Based on this limited information on CRC genomic heterogeneity both in germline and somatic development, before planning treatments with anti-EGFR blockers, it would be critical to investigate the dynamic molecular landscape of CRC in order to suggest the most suitable and hopefully efficient therapy to each patient in a precision medicine environment. Here, EGFR is linked to colorectal carcinoma.